19:55 , Jul 13, 2018 |  BC Week In Review  |  Company News

Aquinox halves workforce after sole clinical asset misses in Phase III

Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) said in an SEC filing it reduced headcount by 30 (53%) and halted all development of sole clinical asset rosiptor (AQX-1125) after the compound missed in a Phase III trial last...
14:46 , Jun 29, 2018 |  BC Week In Review  |  Clinical News

Aquinox discontinues development of rosiptor

Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) said its sole clinical asset, rosiptor (AQX-1125), missed the primary endpoint in the double-blind, international Phase III LEADERSHIP 301 trial to treat interstitial cystitis/bladder pain syndrome (IC/BPS). The company said it...
19:06 , Jun 27, 2018 |  BC Extra  |  Clinical News

Aquinox halts product development, stock nosedives

Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) plummeted $12.97 (85%) to $2.34 Wednesday after sole clinical asset rosiptor (AQX-1125) missed the primary endpoint in the Phase III LEADERSHIP 301 trial to treat interstitial cystitis/bladder pain syndrome (IC/BPS). The...
18:32 , Aug 9, 2017 |  BC Innovations  |  Distillery Techniques

Drug properties

TECHNOLOGY: Physicochemical properties Formulations based on combinations of amino acids, sugars and emulsifiers could enable long-term, low-viscosity storage of high-concentration antibodies. Formulations of low (50 mg/mL), high (150 mg/mL) and ultra-high (175 mg/mL) concentrations of IgG1...
08:00 , Dec 7, 2015 |  BC Week In Review  |  Company News

CPGJ, 3SBio deal

3SBio acquired a majority stake in biosimilar company Shanghai CP Guojian. 3SBio paid RMB1.4 billion ($219.1 million) to raise its stake to 54%. 3SBio had acquired a 7% stake in CP Guojian last year, according...
03:11 , Dec 1, 2015 |  BC Extra  |  Company News

3SBio takes majority stake in CP Guojian

3SBio Inc. (HKSE:1530) acquired a majority stake in biosimilar company Shanghai CP Guojian Pharmaceutical Co. Ltd. (Shanghai, China). 3SBio paid RMB1.4 billion ($213.3 million) to raise its stake to 54%. 3SBio had acquired a 7%...
07:00 , Mar 30, 2015 |  BioCentury  |  Regulation

China gears up for biosimilars

Multinational biosimilars companies that lack manufacturing facilities in China could find themselves at a disadvantage to local rivals in getting biosimilars approved. China FDA clarified in a recently released guideline that while biosimilars will be...
07:00 , Mar 16, 2015 |  BC Week In Review  |  Company News

Gold Coast Therapeutics, Insys deal

Gold Coast granted Insys an exclusive sublicense to develop a combination of cromolyn sodium and cetirizine to treat chronic prostatitis/chronic pelvic pain syndrome ( CP/CPPS). Gold Coast has exclusive rights to the preclinical combination from...
08:00 , Mar 2, 2015 |  BioCentury  |  Finance

China's 3SBio plans 2nd IPO

China's 3SBio Inc. is taking itself public again, filing for an IPO on the Hong Kong Stock Exchange to fund both expansion on the mainland and to build on its beachhead in Europe. While the...
00:24 , Jan 1, 2015 |  BC Extra  |  Financial News

Karolinska raises SEK347.9M

Karolinska Development AB (SSE:KDEV) raised SEK347.9 million ($44.6 million) through the sale of convertible bonds that mature on Dec. 31, 2019, have an 8% annual interest rate and may be converted into series B shares...